David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$862M |
| 2 |
Baidu
BIDU
|
+$752M |
| 3 |
Tencent Music
TME
|
+$426M |
| 4 |
Coca-Cola
KO
|
+$424M |
| 5 |
NVIDIA
NVDA
|
+$383M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$981M |
| 2 |
Wells Fargo
WFC
|
+$673M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$574M |
| 4 |
Moderna
MRNA
|
+$442M |
| 5 |
DuPont de Nemours
DD
|
+$415M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.45% |
| 2 | Consumer Discretionary | 10.49% |
| 3 | Communication Services | 9.04% |
| 4 | Healthcare | 8.89% |
| 5 | Financials | 6.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EXEEL
1926
DELISTED
Expand Energy Corp Class C Warrants
EXEEL
| $3.87M | ﹤0.01% |
+230,136
| New | +$4.08M |
|
1927
Olema Pharmaceuticals
OLMA
$949M
| $3.87M | ﹤0.01% |
+116,529
| New | +$4.99M |
|
1928
ALX Oncology
ALXO
$274M
| $3.85M | ﹤0.01% |
52,258
+45,423
| +665% | +$3.57M |
|
1929
Carlyle Group
CG
$17.5B
| $3.85M | ﹤0.01% |
104,826
+96,453
| +1,152% | +$3.38M |
|
1930
PUT
GDS Holdings
GDS
$6.52B
| $3.85M | ﹤0.01% |
+47,500
| New | +$4.74M |
|
1931
Anterix
ATEX
$1.85B
| $3.85M | ﹤0.01% |
81,536
-16,444
| -17% | -$677K |
|
|
SAND
1932
DELISTED
Sandstorm Gold
SAND
| $3.84M | ﹤0.01% |
565,390
-958,239
| -63% | -$6.42M |
|
1933
AES
AES
$10.5B
| $3.83M | ﹤0.01% |
+143,003
| New | +$3.8M |
|
|
DEA
1934
Easterly Government Properties
DEA
$1.17B
| $3.83M | ﹤0.01% |
+73,907
| New | +$4.07M |
|
|
DX
1935
Dynex Capital
DX
$3.2B
| $3.83M | ﹤0.01% |
202,282
+38,913
| +24% | +$717K |
|
1936
CALL
HCA Healthcare
HCA
$92.5B
| $3.82M | ﹤0.01% |
20,300
-15,700
| -44% | -$2.77M |
|
1937
PUT
Five Below
FIVE
$14.2B
| $3.82M | ﹤0.01% |
20,000
-4,600
| -19% | -$867K |
|
|
GBIO
1938
DELISTED
Generation Bio
GBIO
| $3.81M | ﹤0.01% |
13,406
+11,771
| +720% | +$3.77M |
|
1939
PUT
Lowe's Companies
LOW
$118B
| $3.8M | ﹤0.01% |
20,000
-62,400
| -76% | -$10.7M |
|
|
CHNG
1940
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $3.8M | ﹤0.01% |
172,004
+96,289
| +127% | +$2.23M |
|
1941
Everest Group
EG
$14.6B
| $3.79M | ﹤0.01% |
+15,287
| New | +$3.64M |
|
1942
Manhattan Associates
MANH
$12.6B
| $3.79M | ﹤0.01% |
32,268
+20,410
| +172% | +$2.47M |
|
1943
PUT
Bloom Energy
BE
$64.3B
| $3.79M | ﹤0.01% |
140,000
+60,000
| +75% | +$1.96M |
|
1944
PUT
Alaska Air
ALK
$4.8B
| $3.79M | ﹤0.01% |
54,700
+30,800
| +129% | +$1.85M |
|
|
VAQC
1945
DELISTED
Vector Acquisition Corporation II Class A Ordinary Shares
VAQC
| $3.79M | ﹤0.01% |
+382,462
| New | +$3.81M |
|
1946
PUT
Clorox
CLX
$12.6B
| $3.78M | ﹤0.01% |
19,600
-5,600
| -22% | -$1.08M |
|
1947
Wheels Up
UP
$184M
| $3.78M | ﹤0.01% |
1,887
-1,113
| -37% | -$2.34M |
|
1948
CALL
Celanese
CE
$4.91B
| $3.77M | ﹤0.01% |
+25,200
| New | +$3.46M |
|
|
NARI
1949
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $3.77M | ﹤0.01% |
35,206
-3,699
| -10% | -$384K |
|
1950
ORIX
IX
$43.2B
| $3.74M | ﹤0.01% |
220,440
-10,965
| -5% | -$187K |
|
Similar funds
David Shaw's Q1 2021 Portfolio in Review
As of Q1 2021, David Shaw held 4,712 positions worth $104B, down 7.4% from $112B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
David Shaw withdrew a net $18.3B in Q1 2021, closing 730 positions and reducing 1,773 holdings. Its most notable exit was AstraZeneca, an estimated $214M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Communication Services.
Against the trend, David Shaw opened a new position in Baidu worth $627M.
- David Shaw's largest Q1 2021 buy was Baidu: 2,881,724 shares worth $627M.
- David Shaw added most to Tesla in Q1 2021, an estimated $862M increase.
- David Shaw's biggest Q1 2021 reduction was Amazon, cutting an estimated $981M.
- David Shaw fully exited AstraZeneca in Q1 2021, selling an estimated $214M.
- David Shaw's ten largest holdings make up 9.9% of its $104B portfolio in Q1 2021.
- David Shaw opened 825 new positions and closed 730 in Q1 2021.
- David Shaw's portfolio value fell 7.4% quarter-over-quarter to $104B.
Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.